{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:38:13Z","timestamp":1792737493320,"version":"4.5.0"},"reference-count":32,"publisher":"e-Century Publishing Corporation","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/ebfe5165","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:09:25Z","timestamp":1769483365000},"page":"51-69","source":"Crossref","is-referenced-by-count":1,"title":["CCT5 as a candidate biomarker in bladder cancer: functional validation and mechanistic clues"],"prefix":"10.62347","volume":"16","author":[{"given":"Xiaojun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2026]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I and Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229-263.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F, Masson-Lecomte A, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Seisen T, Soukup V and Sylvester RJ. European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ). Eur Urol 2022; 81: 75-94.","journal-title":"Eur Urol"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM and van Rhijn BWG. Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urol Oncol 2022; 40: 110.e111-110.e119.","DOI":"10.1016\/j.urolonc.2021.10.010"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.3390\/ijms21093360","article-title":"1, ERCC1, p53, FGFR3 and TATI in bladder cancers","volume":"21","author":"Matuszczak","year":"2020","unstructured":"Matuszczak M and Salagierski M. Diagnostic and prognostic potential of biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in bladder cancers. Int J Mol Sci 2020; 21: 3360.","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Patel VG, Oh WK and Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 2020; 70: 404-423.","DOI":"10.3322\/caac.21631"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K and Mshs MD. Bladder cancer: a review. JAMA 2020; 324: 1980-1991.","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 2017; 71: 96-108.","journal-title":"Eur Urol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.str.2012.03.007","article-title":"The molecular architecture of the eukaryotic chaperonin TRiC\/CCT","volume":"20","author":"Leitner","year":"2012","unstructured":"Leitner A, Joachimiak LA, Bracher A, Mönkemeyer L, Walzthoeni T, Chen B, Pechmann S, Holmes S, Cong Y, Ma B, Ludtke S, Chiu W, Hartl FU, Aebersold R and Frydman J. The molecular architecture of the eukaryotic chaperonin TRiC\/CCT. Structure 2012; 20: 814-825.","journal-title":"Structure"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2005.03.024","article-title":"Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways","volume":"121","author":"AJ","year":"2005","unstructured":"McClellan AJ, Scott MD and Frydman J. Folding and quality control of the VHL tumor suppressor proceed through distinct chaperone pathways. Cell 2005; 121: 739-748.","journal-title":"Cell"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1093\/emboj\/19.22.5971","article-title":"Eukaryotic chaperonin CCT stabilizes actin and tubulin folding intermediates in open quasi-native conformations","volume":"19","author":"Llorca","year":"2000","unstructured":"Llorca O, Martín-Benito J, Ritco-Vonsovici M, Grantham J, Hynes GM, Willison KR, Carrascosa JL and Valpuesta JM. Eukaryotic chaperonin CCT stabilizes actin and tubulin folding intermediates in open quasi-native conformations. EMBO J 2000; 19: 5971-5979.","journal-title":"EMBO J"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Kasembeli M, Lau WC, Roh SH, Eckols TK, Frydman J, Chiu W and Tweardy DJ. Modulation of STAT3 folding and function by TRiC\/CCT chaperonin. PLoS Biol 2014; 12: e1001844.","DOI":"10.1371\/journal.pbio.1001844"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1097-2765(03)00244-2","article-title":"The CCT chaperonin promotes activation of the anaphase-promoting complex through the generation of functional Cdc20","volume":"12","author":"Camasses","year":"2003","unstructured":"Camasses A, Bogdanova A, Shevchenko A and Zachariae W. The CCT chaperonin promotes activation of the anaphase-promoting complex through the generation of functional Cdc20. Mol Cell 2003; 12: 87-100.","journal-title":"Mol Cell"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.apsb.2025.03.026","article-title":"Inhibition of CCT5-mediated asparagine biosynthesis and anti-PD-L1 produce synergistic antitumor effects in colorectal cancer","volume":"15","author":"Zhang","year":"2025","unstructured":"Zhang Y, Zhao W, Wu L, Ai T, He J, Chen Z, Wang C, Wang H, Zhou R, Liu C and Zhao L. Inhibition of CCT5-mediated asparagine biosynthesis and anti-PD-L1 produce synergistic antitumor effects in colorectal cancer. Acta Pharm Sin B 2025; 15: 2480-2497.","journal-title":"Acta Pharm Sin B"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.trsl.2023.05.007","article-title":"β-catenin\/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer","volume":"260","author":"Reed","year":"2023","unstructured":"Reed ER, Jankowski SA, Spinella AJ, Noonan V, Haddad R, Nomoto K, Matsui J, Bais MV, Varelas X, Kukuruzinska MA and Monti S. β-catenin\/CBP activation of mTORC1 signaling promotes partial epithelial-mesenchymal states in head and neck cancer. Transl Res 2023; 260: 46-60.","journal-title":"Transl Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bbrc.2021.04.105","article-title":"CCT5 interacts with cyclin D1 promoting lung adenocarcinoma cell migration and invasion","volume":"567","author":"Meng","year":"2021","unstructured":"Meng Y, Yang L, Wei X, Luo H, Hu Y, Tao X, He J, Zheng X, Xu Q, Luo K, Yu G and Luo Q. CCT5 interacts with cyclin D1 promoting lung adenocarcinoma cell migration and invasion. Biochem Biophys Res Commun 2021; 567: 222-229.","journal-title":"Biochem Biophys Res Commun"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"739660","DOI":"10.3389\/fonc.2021.739660","article-title":"Exploring the expression and prognostic value of the TCP1 ring complex in hepatocellular carcinoma and overexpressing its subunit 5 promotes HCC tumorigenesis","volume":"11","author":"Liu","year":"2021","unstructured":"Liu J, Huang L, Zhu Y, He Y, Zhang W, Lei T, Xuan J, Xiao B, Li L, Zhou Q and Sun Z. Exploring the expression and prognostic value of the TCP1 ring complex in hepatocellular carcinoma and overexpressing its subunit 5 promotes HCC tumorigenesis. Front Oncol 2021; 11: 739660.","journal-title":"Front Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41416-022-01747-0","article-title":"CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt\/β-catenin signalling pathway","volume":"126","author":"Li","year":"2022","unstructured":"Li Y, Liu C, Zhang X, Huang X, Liang S, Xing F and Tian H. CCT5 induces epithelial-mesenchymal transition to promote gastric cancer lymph node metastasis by activating the Wnt\/β-catenin signalling pathway. Br J Cancer 2022; 126: 1684-1694.","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1038\/s41388-020-1279-3","article-title":"Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression","volume":"39","author":"He","year":"2020","unstructured":"He J, McLaughlin RP, van der Beek L, Canisius S, Wessels L, Smid M, Martens JWM, Foekens JA, Zhang Y and van de Water B. Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression. Oncogene 2020; 39: 4118-4131.","journal-title":"Oncogene"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3000605241271754","DOI":"10.1177\/03000605241271754","article-title":"Increased CCT5 expression is a potential unfavourable factor promoting the growth of nasopharyngeal carcinoma","volume":"52","author":"Wu","year":"2024","unstructured":"Wu S and Peng L. Increased CCT5 expression is a potential unfavourable factor promoting the growth of nasopharyngeal carcinoma. J Int Med Res 2024; 52: 3000605241271754.","journal-title":"J Int Med Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10549-006-9293-x","article-title":"Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers","volume":"101","author":"Ooe","year":"2007","unstructured":"Ooe A, Kato K and Noguchi S. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Breast Cancer Res Treat 2007; 101: 305-315.","journal-title":"Breast Cancer Res Treat"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41573-020-0070-z","article-title":"Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine","volume":"19","author":"Dey","year":"2020","unstructured":"Dey A, Varelas X and Guan KL. Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine. Nat Rev Drug Discov 2020; 19: 480-494.","journal-title":"Nat Rev Drug Discov"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo pathway: biology and pathophysiology","volume":"88","author":"Ma","year":"2019","unstructured":"Ma S, Meng Z, Chen R and Guan KL. The Hippo pathway: biology and pathophysiology. Annu Rev Biochem 2019; 88: 577-604.","journal-title":"Annu Rev Biochem"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.cell.2015.10.044","article-title":"Hippo pathway in organ size control, tissue homeostasis, and cancer","volume":"163","author":"FX","year":"2015","unstructured":"Yu FX, Zhao B and Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 2015; 163: 811-828.","journal-title":"Cell"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","article-title":"The Hippo signalling pathway and its implications in human health and diseases","volume":"7","author":"Fu","year":"2022","unstructured":"Fu M, Hu Y, Lan T, Guan KL, Luo T and Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther 2022; 7: 376.","journal-title":"Signal Transduct Target Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s12943-023-01856-1","article-title":"CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer","volume":"22","author":"Xie","year":"2023","unstructured":"Xie B, Lin J, Chen X, Zhou X, Zhang Y, Fan M, Xiang J, He N, Hu Z and Wang F. CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer. Mol Cancer 2023; 22: 151.","journal-title":"Mol Cancer"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Sadhukhan P, Feng M, Illingworth E, Sloma I, Ooki A, Matoso A, Sidransky D, Johnson BA 3rd, Marchionni L, Sillé FC, Choi W, McConkey D and Hoque MO. YAP1 induces bladder cancer progression and promotes immune evasion through IL-6\/STAT3 pathway and CXCL deregulation. J Clin Invest 2024; 135: e171164.","DOI":"10.1172\/JCI171164"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","unstructured":"Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.","journal-title":"Methods"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"109726","DOI":"10.1016\/j.biopha.2019.109726","article-title":"Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K\/Akt\/mTOR pathway","volume":"122","author":"Rong","year":"2020","unstructured":"Rong L, Li Z, Leng X, Li H, Ma Y, Chen Y and Song F. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K\/Akt\/mTOR pathway. Biomed Pharmacother 2020; 122: 109726.","journal-title":"Biomed Pharmacother"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/jcmm.13293","article-title":"Emerging role of Hippo signalling pathway in bladder cancer","volume":"22","author":"Xia","year":"2018","unstructured":"Xia J, Zeng M, Zhu H, Chen X, Weng Z and Li S. Emerging role of Hippo signalling pathway in bladder cancer. J Cell Mol Med 2018; 22: 4-15.","journal-title":"J Cell Mol Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/1471-2407-13-349","article-title":"Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder","volume":"13","author":"Liu","year":"2013","unstructured":"Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, Zeng YX, Zhou FJ and Xie D. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder. BMC Cancer 2013; 13: 349.","journal-title":"BMC Cancer"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"10427","DOI":"10.2147\/OTT.S229231","article-title":"Overexpressing CCT6A contributes to cancer cell growth by affecting the G1-To-S phase transition and predicts a negative prognosis in hepatocellular carcinoma","volume":"12","author":"Zeng","year":"2019","unstructured":"Zeng G, Wang J, Huang Y, Lian Y, Chen D, Wei H, Lin C and Huang Y. Overexpressing CCT6A contributes to cancer cell growth by affecting the G1-To-S phase transition and predicts a negative prognosis in hepatocellular carcinoma. Onco Targets Ther 2019; 12: 10427-10439.","journal-title":"Onco Targets Ther"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"7584","DOI":"10.1128\/MCB.18.12.7584","article-title":"Maturation of human cyclin E requires the function of eukaryotic chaperonin CCT","volume":"18","author":"Won","year":"1998","unstructured":"Won KA, Schumacher RJ, Farr GW, Horwich AL and Reed SI. Maturation of human cyclin E requires the function of eukaryotic chaperonin CCT. Mol Cell Biol 1998; 18: 7584-7589.","journal-title":"Mol Cell Biol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:51:03Z","timestamp":1792734663000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/16\/1\/ajcr0169142.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.62347\/ebfe5165","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]}}}